Loading
A phase 3 trial of FE 999326 in bladder & urothelial cancer, run by Ferring Pharmaceuticals, active and no longer recruiting.
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) is a phase 3 interventional study registered as NCT05704244 by Ferring Pharmaceuticals, with 25 participants enrolled, started 2022-12-21 and due to reach its primary completion in 2029-11-30. Interventions recorded: FE 999326.
Shares Ferring Pharmaceuticals, Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Ferring Pharmaceuticals, Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.